ASCO 2026

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

Oncology

ASCO 26: Precision medicine takes a village, with Carolyn So...

In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

ASCO26: Symptom-tracking app helps advanced cancer patients

An app used to support people living with advanced cancer has helped them maintain quality of life, and also kept them out of hospital.

News

Two packets and two vials of different doses of Imfinzi

ASCO26: AZ triplet makes waves in frontline liver cancer

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

ASCO26: Celcuity punished as trial disappoints investors

ASCO26: In vivo CAR-Ts in the spotlight

ASCO 26: Precision medicine takes a village, with Carolyn So...

ASCO26: After negative adcomm, AZ builds case for oral SERD

ASCO26: Symptom-tracking app helps advanced cancer patients

ASCO26: AZ triplet makes waves in frontline liver cancer

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

Discover a new era of healthcare panel engagement: Grounded ...

ASCO 2026

Editor's Picks